We are live on ! Find out more
GTBP icon

GT Biopharma
GTBP

49 hedge funds and large institutions have $69.7M invested in GT Biopharma in 2021 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,653% more capital invested

Capital invested by funds: $3.98M → $69.7M (+$65.7M)

725% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 4

145% more funds holding

Funds holding: 20 → 49 (+29)

125% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 4

0.62% more ownership

Funds ownership: 0.09% → 0.71% (+0.62%)

Holders
49
Holders Change
+29
Holders Change %
+145%
% of All Funds
0.85%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
33
Increased
9
Reduced
4
Closed
4
Calls
$9K
Puts
–
Net Calls
+$9K
Net Calls Change
+$9K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$19.6M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$9.9M
3
Citadel Advisors
Citadel Advisors
Florida
+$7.06M
4
State Street
State Street
Massachusetts
+$5.19M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$3M

Top Sellers

Rank Fund Capital Flow
1
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$290K
2
Millennium Management
Millennium Management
New York
-$191K
3
VF
Virtu Financial
New York
-$156K
4
Squarepoint
Squarepoint
New York
-$113K
5
TRCT
Tower Research Capital (TRC)
New York
-$15K
Name Holding Trade Value Shares
Change 		Change in
Stake
MLICM
26
Metropolitan Life Insurance Company (MetLife)
New York
$136K +$122K +293 New
Bank of America
27
Bank of America
North Carolina
$125K +$112K +269 New
Citigroup
28
Citigroup
New York
$95K +$84.8K +204 New
Royal Bank of Canada
29
Royal Bank of Canada
Ontario, Canada
$55K -$290K -698 -85%
UBS Group
30
UBS Group
Switzerland
$48K -$11.6K -28 -21%
Osaic Holdings
31
Osaic Holdings
Arizona
$45K +$21.2K +51 +109%
Optiver Holding
32
Optiver Holding
Netherlands
$40K +$35.7K +86 New
Legal & General Group
33
Legal & General Group
United Kingdom
$39K +$34.9K +84 New
DWA
34
Dorsey Wright & Associates
California
$38K +$33.7K +81 New
AIP
35
Ameritas Investment Partners
Nebraska
$29K +$25.8K +62 New
Rockefeller Capital Management
36
Rockefeller Capital Management
New York
$26K -$4.16K -10 -15%
TF
37
TimeScale Financial
Massachusetts
$9K – – –
HFM
38
Hartford Financial Management
Connecticut
$8K +$7.06K +17 New
Wells Fargo
39
Wells Fargo
California
$6K +$3.74K +9 +225%
FWM
40
Focused Wealth Management
New York
$5K +$4.16K +10 New
TRCT
41
Tower Research Capital (TRC)
New York
$4K -$15K -36 -80%
HI
42
Harbour Investments
Wisconsin
$2K +$1.25K +3 +300%
ASN
43
Advisory Services Network
Georgia
$2K +$2.08K +5 New
S
44
SignatureFD
Georgia
$2K +$2.08K +5 New
RG
45
Retirement Group
California
$1K – – –
Simplex Trading
46
Simplex Trading
Illinois
$1K +$831 +2 New
APA
47
American Portfolios Advisors
New York
$217 – – –
AIG
48
American International Group
New York
$207 +$185K +445 New
Millennium Management
49
Millennium Management
New York
– -$191K -930 Closed
VF
50
Virtu Financial
New York
– -$156K -758 Closed
1
2
3

GTBP Hedge Fund Activity: Q2 2021 in Review

49 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q2 2021, worth a combined $69.7M — up 1,653% from $3.98M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new GTBP positions and 4 closed out — a net gain of 29 holders — while 9 added to existing stakes and 4 trimmed.

The largest buyer was BlackRock, opening a new position worth an estimated $19.6M. The largest seller was Royal Bank of Canada, cutting an estimated $290K.

  • 49 institutional investors held GT Biopharma (GTBP) as of Q2 2021, up from 20 in Q1 2021.
  • Funds reported $69.7M of GT Biopharma stock for Q2 2021, up 1,653% quarter-over-quarter.
  • 33 funds opened new GT Biopharma positions in Q2 2021 and 4 closed out, a net change of +29 holders.
  • The largest GT Biopharma buyer in Q2 2021 was BlackRock, an estimated $19.6M added.
  • The largest GT Biopharma seller in Q2 2021 was Royal Bank of Canada, an estimated $290K sold.

Based on aggregated 13F filings for Q2 2021.